Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory

Rhea-AI Summary

Nuwellis (Nasdaq: NUWE) announced creation of a dedicated South Texas commercial territory on April 7, 2026 to strengthen hospital engagement and expand access to Aquadex therapy in a region with large hospital systems and leading cardiac and critical care programs.

The focused territory is intended to provide more direct clinical support to physicians and care teams evaluating advanced fluid management strategies, reinforcing Nuwellis’ commercial infrastructure and partnerships with hospitals treating complex cardiorenal patients.

Argus Apr 7 session

+3.67% close to close Open Argus

Details

News Market Reaction – NUWE

On Apr 7, the day this news came out, NUWE closed 3.67% above the previous close.

Data tracked by StockTitan Argus for the Apr 7 session.

Key Figures

Q4 2025 revenue: $2.4 million Full-year 2025 revenue: $8.3 million Q4 2025 gross margin: 68.2% +5 more

Q4 2025 revenue

$2.4 million

Fourth quarter 2025, up 4% year over year and 9% sequentially

Full-year 2025 revenue

$8.3 million

2025 revenue, down 5% versus 2024

Q4 2025 gross margin

68.2%

Fourth quarter 2025 gross margin, improved from 58.4%

2025 net loss

$17.5 million

Full-year 2025 net loss attributable to common shareholders

Cash balance

$1.2 million

Cash, cash equivalents and restricted cash as of December 31, 2025

Cash used in operations

$10.8 million

Cash used in operating activities during 2025

Potential warrant proceeds

$28 million

Maximum cash if all registered warrants under S-3 are exercised

Registered warrant shares

4,279,325 shares

Common shares issuable from previously issued warrants in S-3 filing

Historical Context

5 past events · Latest: Mar 31

5 events

1. Mar 31

   Pediatric segment update

   24h Move

   +0.0%

   Pediatric category reached about half of U.S. revenue with 47 centers.

2. Mar 17

   Acquisition completion

   24h Move

   -8.5%

   Closed Rendiatech acquisition to add automated kidney function monitoring.

3. Mar 10

   Earnings results

   24h Move

   +0.8%

   Reported Q4 growth and margin improvement but weaker full-year revenue.

4. Mar 05

   Clinical leadership hire

   24h Move

   -5.1%

   Appointed clinical strategy director to advance pediatric and cardiorenal focus.

5. Feb 26

   Board appointments

   24h Move

   -3.6%

   Added directors with device commercialization and capital-markets experience.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cardiorenal conditions, aquadex therapy, ultrafiltration therapy, pre-funded warrants, +3 more

7 terms

cardiorenal conditions medical

"a medical technology company committed to delivering solutions for patients with cardiorenal conditions"

Cardiorenal conditions are health problems in which the heart and kidneys affect each other’s function, so damage or stress in one organ can worsen the other—think of the heart as a pump and the kidneys as a filter in a shared system. Investors watch these conditions because they drive demand for drugs, medical devices and ongoing care, influence hospital and insurance costs, and can shape long-term revenue and regulatory risks in healthcare businesses.

aquadex therapy medical

"increases access to Aquadex® therapy across the region"

Aquadex therapy is a medical device-based treatment that gently removes excess fluid from the bloodstream of patients, most often those with heart failure who retain fluid despite medicines. Think of it like a small, targeted pump that draws off surplus water from a flooded basement without disturbing the house’s other systems. Investors watch it because clinical results, regulatory approvals and insurance coverage determine how widely hospitals adopt the technology and how much revenue device makers can earn.

ultrafiltration therapy medical

"implement ultrafiltration therapy,” said Nuwellis’ CEO John Erb"

Ultrafiltration therapy is a medical procedure that uses a machine and a fine filter to remove excess fluid and some dissolved waste directly from a patient’s blood, similar to wringing water out of a sponge without surgery. For investors, its importance lies in potential effects on healthcare utilization and costs—widespread adoption, clinical trial results, device approvals and reimbursement policies can drive revenue for device makers, hospitals and service providers.

pre-funded warrants financial

"shares come from January 2026 pre-funded warrants, common stock purchase warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

common stock purchase warrants financial

"pre-funded warrants, common stock purchase warrants, January inducement warrants"

Common stock purchase warrants are tradable instruments that give the holder the right to buy a company’s common shares at a set price before a specified date, like a coupon that lets you purchase stock later at a fixed rate. They matter to investors because they offer a way to gain future upside if the stock rises, but when exercised they increase the number of shares outstanding and can reduce existing shareholders’ ownership and earnings per share.

placement agent warrants financial

"January inducement warrants, and placement agent warrants."

Placement agent warrants are options given to the broker or intermediary who helps a company sell shares privately; they grant the holder the right to buy a set number of company shares at a fixed price in the future. For investors, these warrants matter because exercising them increases the total shares outstanding and can dilute existing ownership and earnings per share, similar to adding more slices to a pizza and reducing the size of each existing slice.

going concern financial

"raising substantial doubt about its ability to continue as a going concern."

Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region

MINNEAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the creation of a dedicated South Texas commercial territory as part of its ongoing effort to strengthen field engagement in key U.S. hospital markets.

South Texas is a significant healthcare region with large hospital systems and leading cardiac and critical care programs managing patients with complex fluid balance challenges. By establishing a focused territory, Nuwellis aims to provide more direct clinical support to physicians and care teams evaluating advanced fluid management strategies, including Aquadex therapy.

“Expanding our presence in strategic hospital markets enables closer collaborations with clinicians as they evaluate and implement ultrafiltration therapy,” said Nuwellis’ CEO John Erb. “South Texas is home to a number of highly regarded cardiac and critical care programs, and our new territory allows us to deepen our partnerships with those teams.”

The addition of the South Texas territory reflects Nuwellis’ continued focus on strengthening its commercial organization and supporting hospitals treating patients with complex cardiorenal conditions.

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.

About the Aquadex SmartFlow® System

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
ir@nuwellis.com

Media Contact:

CORE PR
media@nuwellis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nuwellis (NUWE) announce on April 7, 2026 about South Texas?

Nuwellis announced a new dedicated South Texas commercial territory to boost hospital engagement and Aquadex access. According to the company, the territory aims to deepen clinical support for physicians and care teams in major cardiac and critical care programs across the region.

How will NUWE’s South Texas territory affect hospital access to Aquadex therapy?

The new territory is designed to increase direct clinical support and access to Aquadex therapy for hospitals. According to the company, focused field coverage will help clinicians evaluate and implement ultrafiltration and advanced fluid management strategies more effectively.

Why is South Texas important for Nuwellis’ commercial strategy (NUWE)?

South Texas is described as a significant healthcare region with large hospital systems and leading cardiac programs. According to the company, the region’s concentration of complex fluid-balance cases makes it a strategic target for deeper clinician partnerships and commercial support.

What operational change did Nuwellis (NUWE) make to strengthen its commercial organization?

Nuwellis created a dedicated South Texas commercial territory to enhance field engagement and hospital support. According to the company, this reflects a continued focus on bolstering its commercial infrastructure and clinician-facing resources in key U.S. markets.

Will NUWE provide more clinical support to physicians in South Texas after April 7, 2026?

Yes. The company says the South Texas territory will provide more direct clinical support to physicians and care teams evaluating advanced fluid management. According to the company, the move is intended to strengthen collaborations around ultrafiltration therapy and Aquadex use.